F
inding a safe and effective HIV/AIDS vaccine that is able to induce protective humoral and cellular immune response to HIV-1 is one of the major research goals in fighting this pandemic affecting the human population worldwide. Currently, only one HIV-1 vaccine tested in a phase III clinical trial (RV144) in Thailand has shown some level of protection against HIV-1, and it is based on a combination of recombinant poxvirus vector ALVAC and the HIV-1 gp120 protein used in a prime-boost protocol that showed 31.2% protection against HIV-1 infection (1) . Since the poxvirus vector appeared to have played a significant role in the protective immune response in the combined protocol, in spite of the poor immunogenicity of the ALVAC vector (2), a main interest in improving the immunogenicity of attenuated poxvirus vectors as future HIV-1 vaccine candidates has emerged (3) (4) (5) .
Among poxviruses, the highly attenuated vaccinia virus (VACV) strain modified VACV Ankara (MVA) is one of the most encouraging vectors, as it has been extensively used in preclinical and clinical trials as a prototype vaccine against HIV-1, infectious diseases, and cancer (6, 7) . Numerous MVA vectors expressing different HIV-1 antigens have been produced and tested in human clinical trials (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , revealing that MVA vectors are safe and elicit humoral and cellular immune responses to HIV-1 antigens (for reviews, see references 3, 6, and 7), regardless of its limited replication in human and most mammalian cell types. However, MVA still contains several immunomodulatory VACV genes that counteract the host antiviral innate immune response, particularly those genes encoding proteins that inhibit the Toll-like receptor (TLR) signaling pathway (26) , an important route that plays a fundamental role in the defense against pathogens through the induction of proinflammatory cytokines and type I interferon (IFN) but also in modeling adaptive immune responses to patho-gens (27) (28) (29) . Hence, the deletion of these immunomodulatory VACV genes is a promising approach to the generation of improved MVA-based vaccines with increasing magnitude, breadth, polyfunctionality, and durability of the antigen-specific cellular and humoral immune responses.
An attractive target for this strategy is the VACV N2L gene. The VACV N2L gene is present in the genome of VACV strains Western Reserve (WR) (VACV-WR_029), Copenhagen (N2L), and MVA (MVA 021L) but absent from NYVAC. N2L encodes a 175-amino-acid protein with a predicted molecular mass of 20.8 kDa (www.poxvirus.org). The VACV N2L gene belongs to the VACV B cell lymphoma 2 (Bcl-2) family (30) , a family of intracellular proteins that are important inhibitors of the TLR signaling pathway, acting at different levels of the route, such as A46 (31) (32) (33) (34) (35) , A52 (31, (36) (37) (38) (39) , B14 (named B15R in MVA) (36, (39) (40) (41) , C6 (42) (43) (44) , K7 (45) (46) (47) (48) , and N1 (49) (50) (51) (52) (53) (54) . Old reports showed that N2L is transcribed early during infection (55) and that a single mutation in its 5=-untranslated region is responsible for resistance to the inhibitor of RNA polymerase II (alpha-amanitin) and for the temperature-sensitive phenotype (56, 57) , but as yet there is no explanation for these observations. Moreover, a yeast two-hybrid assay revealed that N2 binds to importin alpha 1, valosin-containing protein (p97)/p47 complex interacting protein 1 (VCPIP1), and phospholipid scramblase 4 (PLSCR4) (58) , but the biological significance of these interactions is unknown. Recently, it has been reported that the VACV N2L gene encodes a nonessential protein expressed early during infection and located in the nucleus that inhibits the activation of the IFN-␤ promoter by inhibiting IFN regulatory factor 3 (IRF3) activation (59) , although the exact molecular mechanism of action remains unknown. Furthermore, the VACV N2 protein is a virulence factor since a VACV WR strain with N2L deleted was attenuated in murine intranasal and intradermal models (59) . However, the VACV N2L deletion mutant was not more immunogenic than the parental strain after the immunization of mice and the protection afforded against a challenge with virulent WR was indistinguishable from that of control viruses (59) .
Therefore, taking into consideration the role of N2L in blocking the IFN signaling pathway through IRF3, it was of interest to establish its immunomodulatory function in vivo. Hence, in this investigation, we characterized how N2L impacts innate, adaptive, and memory immune responses in mice by examining specific immune responses to HIV-1 and VACV antigens. This was done by deleting the VACV N2L gene from the vector backbone of MVA-B, an HIV/AIDS vaccine candidate based on an attenuated recombinant MVA vector expressing HIV-1 Env and Gag-Pol-Nef (GPN) antigens from clade B (60) . MVA-B has been extensively studied in vitro and in different animal models (42, (60) (61) (62) (63) (64) (65) (66) , where it triggers strong and durable immune responses to HIV-1 antigens. Furthermore, MVA-B was safe and highly immunogenic when tested in a phase I clinical trial with healthy human volunteers, inducing humoral responses to Env and HIV-1-specific CD4 ϩ and CD8 ϩ T cell responses that were high, broad, polyfunctional, and long-lasting (12, 14) . Moreover, a phase I clinical trial of HIV-1-infected patients on highly active antiretroviral therapy with MVA-B as an HIV/AIDS therapeutic vaccine is ongoing.
Here we have examined the innate immune responses (in human macrophages and monocyte-derived dendritic cells [moDCs] ) and evaluated the adaptive and memory HIV-1-specific cellular and humoral immune responses of mice inoculated with MVA-B and the MVA-B ⌬N2L deletion mutant. Our results demonstrate that the VACV N2 protein has an immunomodulatory role and that deleting N2L improves innate, adaptive, and memory HIV-1-specific immune responses. Thus, deletion of N2L from poxvirus vectors could be a general strategy to potentiate the vaccine utility of these vectors.
MATERIALS AND METHODS
Ethics statement. The animal studies described here were approved by the Ethical Committee of Animal Experimentation (CEEA-CNB) of Centro Nacional de Biotecnologia (CNB-CSIC, Madrid, Spain) in accordance with national and international guidelines and with the Royal Decree (RD 1201/2005) (permit no. 12055).
Studies with peripheral blood mononuclear cells (PBMCs) from healthy blood donors recruited by the Centro de Transfusión de la Comunidad de Madrid (Madrid, Spain) were approved by the Ethical Committee of Centro de Transfusión de la Comunidad de Madrid (Madrid, Spain). Written informed consent was obtained from each donor before blood collection for the purpose of this investigation according to a collaborative agreement between the Centro de Transfusión de la Comunidad de Madrid and the CNB-CSIC. All information was kept confidential.
Cells and viruses. DF-1 cells (a spontaneously immortalized chicken embryo fibroblast (CEF) cell line, ATCC catalog no. CRL-12203) and primary CEF cells (obtained from specific-pathogen-free 11-day-old eggs; Intervet, Salamanca, Spain) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). The THP-1 human monocytic cell line (ATCC catalog no. TIB-202) was cultured in RPMI 1640 medium containing 2 mM L-glutamine, 50 M 2-mercaptoethanol, 100 IU/ml penicillin, 100 g/ml streptomycin (complete medium; all from Invitrogen, San Diego, CA) and 10% heat-inactivated FCS (Sigma-Aldrich, St. Louis, MO) as previously described (42, 62, 67) . THP-1 cells were differentiated into macrophages by treatment with 0.5 mM phorbol 12-myristate 13-acetate (Sigma-Aldrich) for 24 h before use. PBMCs from buffy coats of healthy donors (recruited by the Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain) were obtained by Ficoll gradient separation on Ficoll-Paque (GE Healthcare). Next, CD14 ϩ monocytes were purified by depletion with the Dynabeads Untouched human monocytes kit (Invitrogen Dynal AS, Oslo, Norway) in accordance with the manufacturer's protocol. moDCs were then obtained as previously described (62) , after the cultivation of purified monocytes for 7 days in complete RPMI 1640 medium containing 10% heat-inactivated FCS and supplemented with 50 ng/ml granulocyte-macrophage colony-stimulating factor and 20 ng/ml interleukin-4 (IL-4) (both from Gibco-Life Technologies). Cell cultures were maintained at 37°C (CEFs, THP-1 cells, and moDCs) or 39°C (DF-1 cells) in a humidified incubator containing 5% CO 2 . Cell lines were infected with viruses as previously described (60, 67) . Virus infection of all of the cell types was performed with 2% FCS.
The poxvirus strains used in this study included the attenuated wildtype (WT) MVA (MVA-WT) obtained from the Ankara strain after 586 serial passages in CEF cells (derived from clone F6 at passage 585, kindly provided by G. Sutter) and the recombinant MVA-B expressing HIV-1 IIIB GPN as an intracellular polyprotein and the HIV-1 BX08 gp120 protein as a cell-released product from HIV-1 clade B isolates (60) . MVA-B was used as the parental virus for the generation of the MVA-B ⌬N2L deletion mutant. All viruses were grown in primary CEF cells, purified by centrifugation through two 36% (wt/vol) sucrose cushions in 10 mM Tris-HCl (pH 9), and titrated in DF-1 cells by plaque immunostaining assay as previously described (68) . Determinations of the titers of the different viruses were performed at least two times. All viruses were free of contamination with mycoplasmas or other bacteria.
Construction of plasmid transfer vector pGem-RG-N2L wm. Plasmid transfer vector pGem-RG-N2L wm was used for the construction of the MVA-B ⌬N2L deletion mutant from which the VACV N2L gene has been deleted (N2L in the Copenhagen strain of VACV is equivalent to MVA 021L in MVA. For simplicity, throughout this work, we use the open reading frame nomenclature of the Copenhagen strain to refer to the MVA genes). pGem-RG-N2L wm was obtained by sequential cloning of N2L flanking sequences into plasmid pGem-RG wm (4,540 bp), whose generation was previously described (63) , and contains the genes for DsRed2 and red-shifted green fluorescent protein (rsGFP) under the control of the synthetic early/late (sE/L) promoter. The MVA-B genome was used as the template to amplify the right flank of the N2L gene (474 bp) with oligonucleotides RFN2L-AatII-F (5=-GTCTAGGACGTCTAATTTT CATATGG-3=) (AatII site underlined) and RFN2L-XbaI-R (5=-AAGTAT TCTAGAAATTAATGATGC-3=) (XbaI site underlined). The right flank was digested with AatII and XbaI and cloned into plasmid pGem-RG wm, which had previously been digested with the same restriction enzymes, to generate pGem-RG-RFsN2L wm (4,981 bp). The repeated right flank of the N2L gene (474 bp) was amplified by PCR from the MVA-B genome with oligonucleotides RF=N2L-EcoRI-F (5=-GTCTAGGAATTCTAATTT TCATATGG-3=) (EcoRI site underlined) and RF=N2L-ClaI-R (5=-AAGT ATATCGATAATTAATGATGC-3=) (ClaI site underlined), digested with EcoRI and ClaI, and inserted into EcoRI/ClaI-digested pGem-RGRFsN2L wm to generate pGem-RG-RFdN2L wm (5,414 bp). The left flank of the N2L gene (431 bp) was amplified by PCR from the MVA-B genome with oligonucleotides LFN2L-ClaI-F (5=-AGAGGAATCGATGATCGCA TCC-3=) (ClaI site underlined) and LFN2L-BamHI-R (5=-AGCCATGGA TCCACTAATCAGATCTATTAG-3=) (BamHI site underlined), digested with ClaI and BamHI, and inserted into ClaI/BamHI-digested pGem-RGRFdN2L wm. The resulting plasmid, pGem-RG-N2L wm (5,815 bp), was confirmed by DNA sequence analysis and directs the deletion of the N2L gene from the MVA-B genome.
Construction of MVA-B ⌬N2L. The MVA-B ⌬N2L deletion mutant generated in this work contains a deletion of the VACV gene N2L and was constructed by transfecting plasmid transfer vector pGem-RG-N2L wm into DF-1 cells infected with the parental virus MVA-B and then screening for transient Red2-GFP coexpression with the genes for DsRed2 and rs-GFP as the transiently selectable markers as previously described (42, 63) . MVA-B ⌬N2L was finally obtained after six consecutive rounds of plaque purification in DF-1 cells.
PCR analysis of MVA-B ⌬N2L. To verify that the VACV gene N2L deletion in MVA-B ⌬N2L was correctly generated, viral DNA was extracted from DF-1 cells mock infected or infected at 5 PFU/cell with MVA-WT, MVA-B, or MVA-B ⌬N2L as previously described (60) . Primers RFN2L-AatII-F and LFN2L-BamHI-R (described above), spanning N2L flanking regions, were used for PCR analysis of the N2L locus. The amplification protocol was previously described (63) . PCR products were run in 1% agarose gel and visualized by SYBR Safe staining (Invitrogen). The N2L deletion was also confirmed by DNA sequence analysis.
Expression of HIV-1 IIIB GPN and HIV-1 BX08 gp120 proteins by MVA-B ⌬N2L. To check the expression of the HIV-1 IIIB GPN and HIV-1 BX08 gp120 proteins by MVA-B ⌬N2L, monolayers of DF-1 cells were mock infected or infected at 5 PFU/cell with MVA-WT, MVA-B, or MVA-B ⌬N2L. At 24 h postinfection, cells were lysed in Laemmli buffer, cells extracts were fractionated by 8% SDS-PAGE, and evaluated by Western blotting with rabbit polyclonal anti-gp120 antibody against IIIB (Centro Nacional de Biotecnología; diluted 1:3,000) or polyclonal anti-gag p24 serum (ARP 432, diluted 1:1,000; National Institute for Biological Standards and Control [NIBSC] Centre for AIDS Reagents) to analyze the expression of the gp120 and GPN proteins, respectively. As loading controls, we used rabbit anti-␣-tubulin (Cell Signaling, diluted 1:1,000), rabbit anti-␤-actin (diluted 1:1,000; Cell Signaling), and rabbit anti-VACV E3 (diluted 1:1,000; Centro Nacional de Biotecnología) antibodies. A horseradish peroxidase (HRP)-conjugated anti-rabbit antibody (diluted 1:5,000; Sigma) was used as the secondary antibody. The immunocomplexes were detected with an HRP-luminol enhanced-chemiluminescence system (ECL Plus; GE Healthcare).
Analysis of virus growth. To study the virus growth profile of MVA-B ⌬N2L in comparison to that of parental MVA-B, monolayers of DF-1 cells were infected in duplicate at 0.01 PFU/cell with MVA-B or MVA-B ⌬N2L.
Following virus adsorption for 60 min at 37°C, the inoculum was removed. The infected cells were washed with DMEM and incubated with fresh DMEM containing 2% FCS at 37°C in a 5% CO 2 atmosphere. At different times (0, 24, 48, and 72 h) postinfection, cells were collected by scraping, freeze-thawed three times, and briefly sonicated. Virus titers in cell lysates were determined by immunostaining plaque assay as previously described (68) .
RNA analysis by quantitative real-time PCR. Total RNA was isolated from THP-1 cells and moDCs mock infected or infected with MVA-WT, MVA-B, or MVA-B ⌬N2L with the RNeasy kit (Qiagen GmbH, Hilden, Germany). Reverse transcription of at least 500 ng of RNA was performed with the QuantiTect reverse transcription kit (Qiagen GmbH, Hilden, Germany). Quantitative PCR was performed with a 7500 Real-Time PCR system (Applied Biosystems) and Power SYBR green PCR Master Mix (Applied Biosystems) as previously described (67) . The expression levels of the genes for IFN-␤, tumor necrosis factor alpha (TNF-␣), MIP-1␣, RANTES, RIG-I, MDA-5, and hypoxanthine phosphoribosyltransferase (HPRT) were analyzed by real-time PCR with specific oligonucleotides (sequences are available upon request). Specific gene expression was expressed relative to the expression of the gene for HPRT in arbitrary units. All samples were tested in duplicate, and two different experiments were performed with each cell type.
DNA vectors. DNA plasmids expressing HIV-1 IIIB GPN fusion protein (pcDNA-IIIB GPN) and HIV-1 BX08 gp120 (pCMV-BX08 gp120) and the empty plasmid (pcDNA-) have been previously described (60) and were purified with the EndoFree Plasmid Mega kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's protocol and diluted for injection in endotoxin-free phosphate-buffered saline (PBS). pcDNA-(termed DNA-) or a mixture of pcDNA-IIIB GPN and pCMV-BX08 gp120 (termed DNA-B) have been used in the immunization protocol as a prime.
Peptides. HIV-1 peptide pools, with each purified peptide at 1 mg/ml per vial, were provided by BEI Resources, NIH. The peptides covered the Env, Gag, Pol, and Nef proteins present in the consensus sequence of HIV-1 clade B (gp120 from isolate BX08 and GPN from isolate IIIB) as consecutive 15-mers overlapping by 11 amino acids. The HIV-1 BX08 gp120 protein was spanned by the Env-1 and Env-2 peptide pools. The HIV-1 IIIB GPN fusion protein was spanned by the Gag-1, Gag-2, GPN-1, GPN-2, GPN-3, and GPN-4 pools. For immunological analysis, we grouped the peptides into three main pools, Env, Gag, and GPN. The Env pool comprises Env-1 and Env-2, the Gag pool comprises Gag-1 and Gag-2, and the GPN pool comprises GPN-1, GPN-2, GPN-3, and GPN-4.
Mouse immunization schedule. Female BALB/c mice (6 to 8 weeks old) were purchased from Harlan Laboratories and stored in a pathogenfree barrier area of the CNB in accordance to the recommendations of the Federation of European Laboratory Animal Science Associations. A DNA prime-MVA boost immunization protocol was performed as previously described (60, 63) to assay the immunogenicity of MVA-WT, MVA-B, and MVA-B ⌬N2L. Groups of animals (n ϭ 8) received 100 g of DNA-B (50 g of pCMV-BX08 gp120 plus 50 g of pCDNA-IIIB GPN) or 100 g of DNA-(100 g of pcDNA-) by the intramuscular route and 2 weeks later received an intraperitoneal (i.p.) inoculation of 1 ϫ 10 7 PFU of the corresponding recombinant VACV (MVA-WT, MVA-B, or MVA-B ⌬N2L) in 200 l of PBS. Mice primed with sham DNA (DNA-) and boosted with nonrecombinant MVA-WT were used as a control group. At 10 and 52 days after the last immunization, four mice in each group were sacrificed with carbon dioxide (CO 2 ) and their spleens were processed to measure the adaptive and memory immune responses to VACV and HIV-1 antigens, respectively, by intracellular cytokine staining (ICS) assay. Two independent experiments were performed.
ICS assay. The magnitude, polyfunctionality, and phenotypes of the VACV and HIV-1-specific T cell adaptive and memory responses were analyzed by ICS as previously described (42, 62, 63) , with some modifications. After an overnight rest, 4 ϫ 10 6 splenocytes (depleted of red blood cells) were seeded onto M96 plates and stimulated for 6 h in complete RPMI 1640 medium supplemented with 10% FCS containing 1 l/ml Golgiplug (BD Biosciences) to inhibit cytokine secretion; monensin 1ϫ (eBioscience), anti-CD107a-Alexa 488 (BD Biosciences); and the different HIV-1 Env, Gag, and GPN pools of peptides (5 g/ml) or MVAinfected A20 cells (4 ϫ 10 5 A20 cells; 1:10 ratio of MVA-infected A20 cells to splenocytes). Then cells were washed, stained for the surface markers, fixed, permeabilized (Cytofix/Cytoperm kit; BD Biosciences), and stained intracellularly with the appropriate fluorochromes. Dead cells were excluded with the violet LIVE/DEAD stain kit (Invitrogen). The fluorochrome-conjugated antibodies used for functional analyses were CD3-phycoerythrin (PE)-CF594, CD4-allophycocyanin (APC)-Cy7, CD8-V500, IFN-␥-PE-Cy7, TNF-␣-PE, and IL-2-APC. In addition, the antibodies used for phenotypic analyses were CD62L-Alexa 700 and CD127-peridinin chlorophyll protein-Cy5.5. All antibodies were from BD Biosciences. Cells were acquired with a Gallios flow cytometer (Beckman Coulter). Analyses of the data were performed with the FlowJo software version 8.5.3 (Tree Star, Ashland, OR). The number of lymphocytegated events was 10 6 . After gating, Boolean combinations of single functional gates were created with the FlowJo software to determine the frequency of each response based on all possible combinations of cytokine expression or all possible combinations of differentiation marker expression. Background responses detected in negative-control samples were subtracted from those detected in stimulated samples for every specific functional combination.
Antibody measurements by ELISA. The total IgG, IgG1, IgG2a, and IgG3 anti-HIV-1 gp120 MN envelope protein antibodies in pooled sera from immunized mice were measured by enzyme-linked immunosorbent assay (ELISA) as previously described (60, 63) .
Statistical procedures. The statistical significance (*, P Ͻ 0.05; **, P Ͻ 0.005; ***, P Ͻ 0.001) of differences between groups was determined by Student's t test (two tailed, type 3). Statistical analysis of the ICS assay results was realized as previously described (63, 69) , by an approach that corrects measurements for the medium response (RPMI), calculating confidence intervals and P values. Only antigen response values significantly larger than the corresponding RPMI are presented. Background values were subtracted from all of the values used to allow analysis of proportionate representation of responses.
RESULTS

Generation and in vitro characterization of MVA-B ⌬N2L.
To determine whether the VACV gene N2L, encoding an inhibitor of IRF3 (59), might have an immunomodulatory role that, in turn, could influence the immunogenicity profile of antigens delivered from a poxvirus vector, we deleted N2L from the HIV/AIDS vaccine candidate MVA-B (expressing HIV-1 Env, Gag, Pol, and Nef antigens from clade B) (60) , generating the MVA-B deletion mutant termed MVA-B ⌬N2L (see Materials and Methods) and analyzed various properties. Figure 1A shows a diagram of MVA-B ⌬N2L. PCR analysis with primers annealing within N2L flanking regions confirmed the deletion of N2L from MVA-B ⌬N2L (Fig.  1B) . The occurrence of the deletion was confirmed by DNA sequencing of the N2L viral locus (data not shown). Furthermore, the mutant virus was plaque purified several times to obtain a viral stock free of WT contamination. Analysis by Western blotting demonstrated that MVA-B ⌬N2L expressed antigens HIV-1 BX08 gp120 and HIV-1 IIIB GPN as did the parental virus MVA-B (Fig.  1C) . Moreover, the growth kinetics of parental MVA-B and deletion mutant MVA-B ⌬N2L in cultured cells were similar (Fig. 1D) , confirming that the VACV N2 protein is not required for MVA replication.
MVA-B ⌬N2L triggers a strong innate immune response in human macrophages and dendritic cells, upregulating type I IFN, proinflammatory cytokine, and chemokine expression. It has been recently reported that VACV N2 in the virulent WR strain blocks IRF3 and therefore, in response to WR infection, inhibits the IFN-I signaling pathway of the cell (59) . Thus, to determine if similar behavior occurs in MVA, a virus known to markedly enhance the type I IFN response (70, 71), we used realtime PCR to analyze the expression of type I IFN (IFN-␤), the proinflammatory cytokine TNF-␣, chemokines (MIP-1␣ and RANTES), and some key cytosolic sensors (RIG-I and MDA-5) that lead to antiviral IFN production in human THP-1 macrophages mock infected or infected for 3 and 6 h with MVA-WT, MVA-B, and MVA-B ⌬N2L at 5 PFU/cell (Fig. 2A) . The results showed that, compared to MVA-WT and MVA-B, MVA-B ⌬N2L significantly upregulated the mRNA levels of IFN-␤, TNF-␣, MIP-1␣, RANTES, as well as RIG-I and MDA-5 ( Fig. 2A) , clearly affecting the IFN-I signaling pathway.
Furthermore, to verify that the VACV N2 protein impairs the IFN-I signaling pathway in innate immune cells, we infected human moDCs with MVA-WT, MVA-B, and MVA-B ⌬N2L at 1 PFU/cell and measured IFN-␤, TNF-␣, MIP-1␣, RANTES, RIG-I, and MDA-5 mRNA levels at 6 h postinfection (Fig. 2B) . Similar to the results obtained with human THP-1 cells, MVA-B ⌬N2L strongly increased IFN-␤, TNF-␣, and MDA-5 expression in moDCs, in contrast to MVA-WT and MVA-B (Fig. 2B) .
Thus, deletion of N2L from the MVA-B genome promotes a strong innate immune response in human macrophages and moDCs, with high expression of type I IFN, proinflammatory cytokines, chemokines, and some key cytosolic sensors that lead to antiviral IFN production, confirming the role of the VACV N2 protein in blocking the IFN-I signaling pathway.
MVA-B ⌬N2L enhances the magnitude and polyfunctionality of HIV-1-specific T cell adaptive immune responses. Given the immunomodulatory role of the VACV N2 protein in impairing the innate immune responses in human macrophages and DCs, we next asked if deletion of VACV N2L from MVA-B may have an impact on the immunogenicity of the vector. Therefore, to study in vivo the effect of N2L deletion on the cellular immunogenicity of the MVA vector expressing HIV-1 antigens, we analyzed the HIV-1-specific immune responses induced by MVA-B ⌬N2L in BALB/c mice with a DNA prime (100 g of DNA-B)-MVA boost (1 ϫ 10 7 PFU) immunization protocol (see Materials and Methods). Animals primed with sham DNA (DNA-) and boosted with nonrecombinant MVA-WT were used as a control group. Adaptive HIV-1-specific T cell immune responses elicited by the different immunization groups (DNA-B-MVA-B, DNA-B-MVA-B ⌬N2L, and DNA--MVA-WT) were measured 10 days after the boost by polychromatic ICS assay, after the stimulation of splenocytes with pools of peptides (Env, Gag, and GPN pools) that spanned the HIV-1 Env, Gag, Pol, and Nef regions from an HIV-1 clade B consensus sequence.
The magnitude of the total HIV-1-specific CD4 ϩ and CD8 ϩ T cell adaptive immune responses (determined as the sum of the individual responses producing IFN-␥, TNF-␣, and/or IL-2 cytokines, as well as the expression of CD107a on the surface of activated T cells as an indirect marker of cytotoxicity) obtained for the Env, Gag, and GPN peptide pools was significantly greater in the DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L immunization groups than in the DNA--MVA-WT control group (P Ͻ 0.001) (Fig. 3A) . The DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L immunization groups triggered an overall HIV-1-specific immune response mediated mainly by CD8 ϩ T cells (80%) (Fig. 3A) . Interestingly, immunization with DNA-B-MVA-B ⌬N2L elicited a significantly greater magnitude of total HIV-1-specific CD4 ϩ and CD8 ϩ T cell responses than DNA-B-MVA-B, with increases of 2.04-and 1.96-fold, respectively (P Ͻ 0.001) (Fig. 3A) .
The pattern of HIV-1-specific T cell adaptive immune responses showed that CD4 ϩ and CD8 ϩ T cell responses were directed mainly against the Env pool in both the DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L immunization groups, with CD8 ϩ T cell responses broadly distributed among Env, GPN, and Gag. However, DNA-B-MVA-B ⌬N2L significantly enhanced the magnitude of Env-and GPN-specific CD4 ϩ and CD8 ϩ T cell responses (P Ͻ 0.001) (Fig. 3B) .
Furthermore, HIV-1-specific CD4 ϩ T cells producing TNF-␣ or IL-2 and HIV-1-specific CD8 ϩ T cells producing CD107a, IFN-␥, or TNF-␣ are the most induced populations in both immunization groups (Fig. 3C) . However, DNA-B-MVA-B ⌬N2L induced a significantly greater magnitude of HIV-1-specific CD4 ϩ and CD8 ϩ T cells producing CD107a, IFN-␥, TNF-␣, or IL-2 than DNA-B-MVA-B did (P Ͻ 0.001) (Fig. 3C ).
The quality of the HIV-1-specific T cell adaptive immune response was characterized in part by the pattern of cytokine production and its cytotoxic potential. Thus, on the basis of the production of CD107a, IFN-␥, TNF-␣, and IL-2 from HIV-1-specific CD4 ϩ and CD8 ϩ T cells, 15 different HIV-1-specific CD4 ϩ and CD8 ϩ T cell populations could be identified (Fig. 4) . As shown in (Fig. 4A, bars) . On the other hand, as shown in Fig. 4B , DNA-B-MVA-B ⌬N2L significantly enhanced the polyfunctionality profile of HIV-1-specific CD8 ϩ T cell responses, with 86% of the CD8 ϩ T cells exhibiting three or four functions, compared to DNA-B-MVA-B, where 59% of the CD8 ϩ T cells exhibited three or four functions (Fig. 4B) . CD8 ϩ T cells producing CD107a, IFN-␥, TNF-␣, and IL-2 or CD107a, IFN-␥, and TNF-␣ were the most abundant populations elicited by parental MVA-B and MVA-B ⌬N2L. However, DNA-B-MVA-B ⌬N2L induced a significantly greater increase in the percentage of each of these populations than DNA-B-MVA-B did (P Ͻ 0.001) (Fig. 4B) .
In summary, these results demonstrate that deletion of VACV gene N2L from the MVA-B genome enhanced the magnitude and quality of HIV-1-specific CD4 ϩ and CD8 ϩ T cell adaptive immune responses. Similar findings were obtained in two independent experiments. (Fig. 5A) . However, the magnitude of VACV-specific CD8 ϩ T cell adaptive immune responses was significantly greater in the DNA--MVA-WT immunization group than that elicited by DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L, with an increase of 2.5-to 2.6-fold (P Ͻ 0.001) (Fig. 5A ) and no differences between the MVA-B and MVA-B ⌬N2L HIV/AIDS vaccine candidates. This is likely due to the expression of HIV-1 antigens acting as competitors for immune dominance of MVA antigens.
Moreover, VACV-specific CD8 ϩ T cells producing CD107a, IFN-␥, or TNF-␣ were the most induced populations in all of the immunization groups (Fig. 5B) . However, DNA--MVA-WT in- duced a significantly greater magnitude of VACV-specific CD8 ϩ T cells producing CD107a, IFN-␥, or TNF-␣ than DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L did (P Ͻ 0.001) (Fig. 5B) .
The quality of VACV-specific CD8 ϩ T cell adaptive immune responses was characterized by the production of CD107a, IFN-␥, TNF-␣, and/or IL-2, where 15 distinct VACV-specific CD8 ϩ T cell populations could be identified (Fig. 5C ). VACV-specific CD8 ϩ T cell responses were similarly polyfunctional in all of the immunization groups, with 61 to 69% of the CD8 ϩ T cells exhibiting three or four functions. CD8 ϩ T cells producing CD107a, IFN-␥, TNF-␣, and IL-2; CD107a, IFN-␥, and TNF-␣; CD107a and TNF-␣; or only CD107a were the most induced populations elicited by all of the immunization groups. However, DNA--MVA-WT induced a significantly greater percentage of most of these populations than DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L did (P Ͻ 0.001) (Fig. 5C) .
Overall, these results showed that MVA-B and MVA-B ⌬N2L elicited similar magnitudes and qualities of VACV-specific CD8 MVA-B ⌬N2L improved HIV-1-specific T cell memory immune responses. Memory T cell responses might be critical for protection against HIV-1 infection (72) (73) (74) (75) , and the durability of a vaccine-induced T cell response is an important feature since long-term protection is a requirement for prophylactic vaccination. Thus, we analyzed HIV-1-specific T cell memory immune responses elicited by the different immunization groups 52 days after the boost by using the ICS assay and a protocol similar to that used in the adaptive phase.
The magnitude of HIV-1-specific CD4 ϩ and CD8 ϩ T cell memory immune responses, determined as the sum of the individual responses producing CD107a, IFN-␥, TNF-␣, and/or IL-2 obtained with the Env, Gag, and GPN peptide pools, was significantly greater in the DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L immunization groups than that elicited by the DNA--MVA-WT control group (P Ͻ 0.001) (Fig. 6A) . Similar to the results obtained in the adaptive phase, the DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L immunization groups triggered an overall HIV-1-specific immune response mediated mainly by CD8 ϩ T cells (Ͼ93%) (Fig. 6A) . However, immunization with DNA-B-MVA-B ⌬N2L again elicited a significantly greater magnitude of HIV-1-specific CD4 ϩ and CD8 ϩ T cell responses than DNA-B-MVA-B did, with increases of 2.4-and 2.23-fold, respectively (P Ͻ 0.001) (Fig. 6A) .
The pattern of HIV-1-specific T cell memory immune responses showed that CD4 ϩ and CD8 ϩ T cell responses were directed mainly against the Env pool in both the DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L immunization groups, with CD8 ϩ T cell responses broadly distributed among Env, GPN, and Gag ( Fig. 6B) , similar to the results obtained in the adaptive phase. However, again DNA-B-MVA-B ⌬N2L significantly enhanced the magnitude of Env-specific CD4 ϩ T cell memory responses and Env-, Gag-and GPN-specific CD8 ϩ T cell memory responses (P Ͻ 0.001) (Fig. 6C) .
Furthermore, HIV-1-specific CD4 ϩ T memory cells producing TNF-␣ or IL-2 and HIV-1-specific CD8 ϩ T memory cells producing CD107a, IFN-␥, or TNF-␣ immunomodulatory molecules are the most induced populations in both immunization groups (Fig.  6D) , similar to the results obtained in the adaptive phase. However, again DNA-B-MVA-B ⌬N2L induced a significantly greater magnitude of HIV-1-specific CD4 ϩ and CD8 ϩ T memory cells producing CD107a, IFN-␥, TNF-␣, or IL-2 than DNA-B-MVA-B did (P Ͻ 0.001) (Fig. 6D) .
The quality of the HIV-1-specific T cell memory immune responses was characterized by analyzing the simultaneous production of CD107a, IFN-␥, TNF-␣, and/or IL-2 from HIV-1-specific CD4 ϩ and CD8 ϩ T cells (Fig. 7) , where 15 distinct HIV-1-specific CD4 ϩ and CD8 ϩ T cell populations could be identified. As shown in (Fig. 7A) , similar to the results obtained in the adaptive phase. On the other hand, as shown in Fig. 7B , HIV-1-specific CD8 ϩ T cell memory responses were highly and similarly polyfunctional in groups immunized with DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L (90% of the CD8 ϩ T cells exhibiting three or four functions in both groups). Again, CD8 ϩ T cells producing CD107a, IFN-␥, TNF-␣, and IL-2 or CD107a, IFN-␥, and TNF-␣ were the most abundant populations elicited by parental MVA-B and MVA-B ⌬N2L. However, DNA-B-MVA-B ⌬N2L induced a significantly greater increase in the percentage of each of these populations than DNA-B-MVA-B did (P Ͻ 0.001) (Fig. 7B) .
Moreover, we also determined the phenotype of the Env-, Gag-, and GPN-specific CD4 ϩ and CD8 ϩ T memory cells by measuring the expression of the CD127 and CD62L surface markers, which allow the definition of the different memory subpopulations: central memory (TCM, CD127 ϩ /CD62L ϩ ), effector memory (TEM, CD127 ϩ /CD62L Ϫ ), and effector (TE, CD127 -/ CD62L Ϫ ) T cells (76) (Fig. 8) . The results showed that in the DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L immunization groups, HIV-1-specific CD4 ϩ and CD8 ϩ T memory cells (determined as the sum of the individual responses producing CD107a, IFN-␥, TNF-␣, and/or IL-2 obtained for the Env, Gag, and GPN peptide pools) were mainly of the TEM phenotype (Fig. 8, bottom  part) , but immunization with MVA-B ⌬N2L induced a significantly greater increase in the percentage of HIV-1-specific CD4 ϩ and CD8
ϩ TEM and TE cells than immunization with MVA-B did (P Ͻ 0.001) (Fig. 8, upper part) .
In summary, these results demonstrate that deletion of VACV gene N2L from the MVA-B genome enhanced the magnitude and quality of HIV-1-specific CD4 ϩ and CD8 ϩ T cell memory immune responses, with an increase in the percentage of TEM and TE cells. Similar findings were obtained in two independent experiments. mune responses elicited by the different immunization groups were measured by ICS assay 52 days after the boost. Similar to the results obtained in the adaptive phase, all of the immunization groups triggered an overall VACV-specific memory immune responses mediated mainly by CD8 ϩ T cells, determined as the sum of the individual responses producing CD107a, IFN-␥, TNF-␣, and/or IL-2 obtained with MVA-infected A20 cells (Fig. 9A) . However, the magnitude of VACV-specific CD8 ϩ T cell memory immune responses in the DNA--MVA-WT immunization group was significantly greater than that elicited by DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L, with increases of 2.94-and 2.27-fold, respectively (P Ͻ 0.001) (Fig. 9A) . Furthermore, DNA-B-MVA-B ⌬N2L induced a significantly greater magnitude of VACV-specific CD8 ϩ T cell memory immune responses than DNA-B-MVA-B, with an increase of 1.3-fold (P Ͻ 0.001) (Fig. 9A) .
MVA-B ⌬N2L improved vector VACV-specific T cell memory immune responses. The VACV-specific T cell memory im-
Moreover, VACV-specific CD8 ϩ T memory cells producing CD107a, IFN-␥, or TNF-␣ are the most induced populations in all of the immunization groups (Fig. 9B) . However, DNA--MVA-WT induced a significantly greater magnitude of VACVspecific CD8 ϩ T memory cells producing CD107a, IFN-␥, TNF-␣, or IL-2 than DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L did (P Ͻ 0.001) (Fig. 9B) . Furthermore, DNA-B-MVA-B ⌬N2L induced a significantly greater magnitude of VACV-specific CD8 ϩ T memory cells producing CD107a, IFN-␥, or TNF-␣ than DNA-B-MVA-B did (P Ͻ 0.001) (Fig. 9B) .
The quality of VACV-specific CD8 ϩ T cell memory immune responses was characterized by the simultaneous production of CD107a, IFN-␥, TNF-␣, and/or IL-2, similar to the protocol followed in the adaptive phase, where 15 distinct VACV-specific CD8 ϩ T cell populations could be identified (Fig. 9C) . VACVspecific CD8 ϩ T cell responses were highly and similarly polyfunctional in all of the immunization groups, with 83 to 88% of the CD8 ϩ T cells exhibiting three or four functions. CD8 ϩ T cells producing CD107a, IFN-␥, TNF-␣, and IL-2; CD107a, IFN-␥, and TNF-␣; or CD107a and TNF-␣ were the most induced populations elicited by all of the immunization groups. However, DNA--MVA-WT induced a significantly greater percentage of these populations than DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L did (P Ͻ 0.001) (Fig. 9C) . Furthermore, DNA-B-MVA-B ⌬N2L induced a significantly greater magnitude of triple and double VACV-specific CD8 ϩ T memory cells producing CD107a, IFN-␥, TNF-␣, or IL-2 than DNA-B-MVA-B did (P Ͻ 0.001) (Fig. 9C) .
Additionally, the analysis of the memory phenotype of VACVspecific CD8 ϩ T memory cells by measuring the expression of the CD127 and CD62L surface markers showed that all of the immunization groups elicited mainly VACV-specific CD8 ϩ T memory cells of the TEM phenotype (Fig. 9D ), but immunization with MVA-WT induced a significantly greater percentage of VACVspecific CD8
ϩ TEM and TE cells than MVA-B and MVA-B ⌬N2L did (P Ͻ 0.001) (Fig. 9D) . Furthermore, MVA-B ⌬N2L elicited a significantly higher percentage of VACV-specific CD8 ϩ TEM cells than MVA-B did (P Ͻ 0.001) (Fig. 9D) .
In summary, these results show that MVA-B ⌬N2L elicited a greater magnitude and quality of VACV-specific CD8 ϩ T cell memory immune responses than MVA-B did, with also an increase in the percentage of TEM cells, but both immunization groups elicited a lower percentage than MVA-WT did. Similar findings were obtained in two independent experiments.
MVA-B ⌬N2L enhances the levels of antibodies against HIV-1 gp120 in the memory phase. Since cells infected with MVA-B release monomeric gp120 (60) and both the cellular and humoral arms of the immune system are thought to be necessary to control HIV-1 infection (77), we analyzed the humoral responses elicited after immunization with DNA-B-MVA-B and DNA-B-MVA-B ⌬N2L, quantifying by ELISA the total IgG and subclass IgG1, IgG2a, and IgG3 levels of antibodies against HIV-1 Env (clade B) in pooled sera obtained from mice 10 and 52 days postboost (Fig. 10) . The results showed that in the group boosted with MVA-B ⌬N2L, the levels of total IgG, IgG1, IgG2a, and IgG3 anti-gp120 antibodies were significantly higher than those obtained in animals immunized with parental MVA-B only in the memory phase. These results indicate that MVA-B and MVA-B ⌬N2L induced antibodies against HIV-1 gp120, and deletion of VACV gene N2L produces in mice an increase of around 2-fold in the humoral memory immune response to HIV-1 Env.
DISCUSSION
Poxvirus vectors are promising HIV/AIDS vaccine candidates, and several recombinant poxvirus vectors (such as the MVA, NYVAC, canarypox, and fowlpox viruses) expressing different HIV-1 antigens have been widely used in many human clinical trials, proving that they are safe and immunogenic, inducing HIV-1-specific humoral and cellular immune responses (for reviews, see references 3-5 and 7). In fact, the canarypox ALVAC combined with HIV-1 gp120 protein is actually the only HIV/AIDS vaccine candidate that is able to trigger a 31.2% protective effect (1) . However, this efficacy is modest, and the immunogenicity against HIV-1 antigens induced by all of the poxvirus vectorbased HIV vaccines tested in human clinical trials is limited and restricted. Thus, new, more efficient, and optimized poxvirus vector-based HIV vaccines able to enhance humoral and cellular immunogenicity against HIV-1 antigens are needed. Different approaches have been developed to improve vector immunogenicity, such as the use of attenuated, replication-competent poxvirus vectors; combination of heterologous vectors; the use of costimulatory molecules, and removal of VACV viral genes encoding immunosuppressive molecules (reviewed in reference 3). The latter is one of the most promising strategies actually developed.
Several MVA deletion mutants containing deletions in different immunomodulatory VACV genes have been generated and analyzed in mice (42, 62, 63, (78) (79) (80) and nonhuman primates (81, 82) . These studies revealed that MVA vectors with deletions of single VACV genes encoding inhibitors of the type I IFN signaling pathway (C6L [42] ), apoptosis (F1L [80] ), and IL-18 binding protein (C12L [79] ) or the uracyl-DNA glycosylase gene (UDG [82] ) enhanced the overall immune responses to HIV-1 antigens. (81) , but an additional fifth deletion of the uracil-DNA glycosylase gene (MVA101R) decreased the responses (81) . Moreover, NYVAC vectors with a single deletion of a VACV gene encoding a TLR inhibitor (A46R [83] ) and with single or double deletions in VACV genes encoding type I and II IFN binding proteins (B19R and B8R, respectively [84] [85] [86] ) were also able to enhance the immune responses to HIV-1 antigens in mice.
Thus, as a way to try to improve the immune responses to HIV-1 antigens by selective deletion of VACV immunomodulatory genes in a poxvirus vector-based HIV vaccine candidate, we focused this work on VACV N2L, a gene whose product we predicted by bioinformatic comparison to belong to a family of VACV proteins with a Bcl-2 fold and with an immunomodulatory role (30) . Recently, it has been demonstrated that VACV N2L encodes a nuclear inhibitor of IRF3 that blocks the IFN I signaling pathway at the intracellular level (59) . As part of our effort to find out the immunomodulatory role of the VACV Bcl-2 family of proteins (30), here we deleted the VACV N2L gene from an MVA vector-based HIV/AIDS vaccine candidate termed MVA-B, which expresses HIV-1 Env, Gag, Pol, and Nef antigens from clade B (60) and has been well characterized in vitro (61, 65) , in mice (42, 60, (62) (63) (64) , in nonhuman primates (66) , and in a phase I clinical trial in humans (12, 14) , showing that MVA-B is a promising HIV/ AIDS vaccine candidate that is safe, highly immunogenic, and able to induce broad, polyfunctional, and durable CD4 ϩ and CD8 ϩ T cell responses to HIV-1 antigens, together with humoral responses to Env.
To examine the immunomodulatory role of N2L, we used mice immunized in DNA prime-MVA boost protocols to compare the innate, adaptive, and memory immune responses to HIV-1 antigens induced by parental MVA-B and the deletion mutant MVA-B ⌬N2L. First, our results showed that deletion of the VACV N2L gene from the MVA-B genome has no effect on the replication capacity of the virus in cultured cells, showing that N2L is not essential for viral replication; similar behavior was observed when N2L was deleted from the WR strain (59) . Moreover, this deletion has no effect on the expression of gp120 and GPN HIV-1 antigens from MVA-B. Furthermore, MVA-B ⌬N2L prompts the upregulation in infected human macrophages and moDCs of type I IFN (IFN-␤), the proinflammatory cytokine TNF-␣, chemokines (MIP-1␣ and RANTES), and some key cytosolic sensors that lead to antiviral IFN production (RIG-I and MDA-5), revealing that the innate immune responses are enhanced by selective deletion of the VACV N2L gene and confirming the role of the VACV N2 protein in blocking the IFN-I signaling pathway (59) . Remarkably, compared to MVA-B, the deletion mutant MVA-B ⌬N2L significantly enhanced the adaptive and memory HIV-1-specific T cell immune responses. In both immunization groups, HIV-1-specific CD4 ϩ and CD8 ϩ T cells were activated, but with a higher frequency of HIV-1-specific CD8 ϩ T cells, similar to previous results with MVA or NYVAC vectors containing deletions in VACV genes (42, 62, 63, 80, 84) . However, MVA-B ⌬N2L significantly enhanced the magnitude of the overall adaptive and memory HIV-1-specific CD4 ϩ and CD8 ϩ T cell responses compared to MVA-B. Furthermore, both immunization groups elicited similar polyfunctional profiles of adaptive and memory HIV-1-specific CD4 ϩ and CD8 ϩ T cells, but MVA-B ⌬N2L significantly enhanced the magnitude of these polyfunctional HIV-1-specific CD4 ϩ and CD8 ϩ T cells producing CD107a, IFN-␥, TNF-␣, or IL-2. In the memory phase, both immunization groups elicited an HIV-1-specific T cell response mainly due to the TEM phenotype, but MVA-B ⌬N2L significantly enhanced the magnitude of these TEM cells, an important and relevant feature because the presence of TEM has been correlated with protection in the macaque-simian immunodeficiency virus model (87, 88) . Interestingly, both immunization groups were able to induce HIV-1-specific CD4 ϩ and CD8 ϩ T cell responses of TEM and TE phenotypes in the adaptive phase (data not shown), with again MVA-B ⌬N2L significantly enhancing the magnitude of CD4 ϩ and CD8 ϩ TEM and TE cells. The fast acquisition of TEM and TE phenotypes in the adaptive phase could be important in developing the T cell memory responses and mounting more effective immunity during a primary pathogen encounter. Moreover, adaptive and memory CD4 ϩ T cell immune responses were directed mainly against Env in both immunization groups. In contrast to other MVA-B deletion mutants previously characterized, where a pattern of GPN-specific CD8 ϩ T cell immune responses was induced (42, 62, 63) , MVA-B ⌬N2L triggered CD8 ϩ T cell immune responses preferentially directed against Env. The biological relevance of this shift is not known. Moreover, a similar CD8 ϩ T cell immune response to Gag and GPN pools was observed after immunization with MVA-B and MVA-B ⌬N2L in the memory phase, indicating that the response to the GPN region is directed mainly to Gag. Furthermore, this enhanced HIV-1-specific CD4 ϩ and CD8 ϩ T cell response elicited after the immunization of mice with MVA-B ⌬N2L is similar to what we have previously reported after deleting from the MVA-B genome other VACV genes that block the IFN-I signaling pathway at the intracellular level, such as C6L (42, 62) or K7R (62) , or when we deleted other VACV genes, such as A41L and B16R (63) . These findings once more reinforce the deletion strategy as a useful approach to improving the HIV-1-specific immune responses elicited by poxvirus vector-based HIV/AIDS vaccine candidates.
On B cell immune activation, MVA-B ⌬N2L induced higher levels of total IgG, IgG1, IgG2a, and IgG3 anti-gp120 humoral responses than MVA-B did in the memory phase. This enhancement may be mediated by the increase in innate immune responses and HIV-1-specific CD4 ϩ T helper cells triggered by the MVA-B ⌬N2L deletion mutant. Thus, the generation of antibodies against gp120 by MVA-B ⌬N2L is a positive immune parameter. In fact, a humoral response to V 1 /V 2 loops of HIV-1 gp120 has been correlated with efficacy in the RV144 phase III clinical trial (89) .
In addition to an evaluation of the immune responses to HIV-1 antigens, we have also analyzed the adaptive and memory specific immune responses directed against the poxvirus vector. The results showed that in the adaptive phase, immunization with MVA-B and MVA-B ⌬N2L elicited similar VACV-specific T cell immune responses due mainly to CD8 ϩ T cells, although the values were significantly lower than those elicited in the control group by MVA-WT. However, in the memory phase, MVA-B ⌬N2L induced a significantly greater magnitude of VACV-specific CD8 ϩ T cell responses than MVA-B did, but again, the response was significantly weaker than that elicited by MVA-WT. Similar results were also obtained by analyzing the response to VACV peptides E3 and F2 (data not shown). The fact that immunization with MVA-WT elicited greater adaptive and memory VACV-specific immune responses than MVA-B and MVA-B ⌬N2L did could be related to competition between the HIV-1 and VACV antigens, diminishing the overall VACV-specific immune responses. On the other hand, the increase in memory VACV-specific immune responses by MVA-B ⌬N2L, compared to MVA-B, could reflect a long-term role of the VACV N2L gene, increasing both VACV and HIV-1 memory immune responses.
How does the deletion of N2L affect the immune responses elicited by MVA-B? As recently reported, N2L is a nuclear inhibitor of IRF3 (59) and therefore acts on the IFN signaling pathway, inhibiting this important route involved in the host antiviral response (27) (28) (29) . Thus, once N2L is deleted from the MVA genome, the IFN signaling pathway should be reestablished upon viral infection, and consequently an upregulation of type I IFN, proinflammatory cytokines, and chemokines should be produced, which will finally activate the antigen-specific T cells. As predicted, this phenomenon was clearly observed in our study, where enhanced expression of type I IFN, proinflammatory cytokines, and chemokines was observed after the infection of human macrophages and moDCs with MVA with the VACV N2L gene deleted. Moreover, the enhanced adaptive and memory HIV-1-specific T cell immune responses elicited in mice by the MVA-B ⌬N2L deletion mutant could be explained by the biological role of N2L. Thus, after the i.p. inoculation of mice with MVA-B ⌬N2L, the enhanced secretion of type I IFN, proinflammatory cytokines, and chemokines induced by MVA-B ⌬N2L-infected macrophages could prompt a greater recruitment of immature DCs and lymphocytes, producing a suitable environment for the uptake and presentation of the HIV-1 antigens to T cells. Immature MVA-B ⌬N2L-infected DCs then migrate to the lymph nodes, maturing en route, and then activate HIV-1-specific T cells, increasing immunogenicity against HIV-1 antigens. In agreement with this, it has been recently reported that on days 5 and 7 postinfection, the total number of cells in the bronchoalveolar lavage fluid of mice immunized intranasally with a VACV WR N2L deletion mutant was higher than in that of mice immunized with the parental virus (59) .
While the WR strain with N2L deleted is attenuated in mice and is not more immunogenic than the parental virus (59), however, the MVA-B ⌬N2L deletion mutant generated in this study is able to enhance immunogenicity against HIV-1 and VACV antigens. This could be due to the difference between the two vectors in the number of immunomodulatory genes (90) (91) (92) .
Overall, our findings have revealed the immunomodulatory role of N2L, proving that its deletion from the MVA-B vector led to an enhanced innate immune response and improvements in the magnitude and quality of adaptive and memory HIV-1-specific CD4 ϩ and CD8 ϩ T cell immune responses. The selective deletion of the N2L viral immunomodulatory gene is important for the optimization of MVA vectors as HIV-1 vaccines.
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